Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

BRL-37344

Adrenergic receptor ligand
 
BML-AR108-0005 5 mg 108.00 USD
Do you need bulk/larger quantities?
 
Potent selective agonist of the ß3-adrenergic receptor. Stimulates lipolysis in white adipocytes and lipolysis/thermogenesis in brown adipocytes.

Product Specification

Formula:C19H21ClNO4 . Na
 
MW:385.8
 
CAS:114333-71-0
 
Purity:≥98% (HPLC)
 
Identity:Determined by 1H-NMR and MS.
 
Appearance:White powder.
 
Solubility:Soluble in water.
 
Shipping:Ambient
 
Long Term Storage:Ambient
 
bml-ar108
Please mouse over
bml-ar108

Product Literature References

Coexisting beta-adrenoceptor subtypes: significance for thermogenic process in brown fat cells: J. Zhao, et al.; Am. J. Physiol. 267, C969 (1994), Abstract;
Correlation of beta 3-adrenoceptor-induced activation of cyclic AMP-dependent protein kinase with activation of lipolysis in rat white adipocytes: G. J. Murphy, et al.; Biochem. Pharmacol. 46, 575 (1993), Abstract;
Radioligand binding studies of the atypical beta 3-adrenergic receptor in rat brown adipose tissue using [3H]CGP 12177: P. Muzzin, et al.; FEBS Lett. 298, 162 (1992), Abstract;
An adipose tissue-specific beta-adrenergic receptor Molecular cloning and down-regulation in obesity: P. Muzzin, et al.; J. Biol. Chem. 266, 24053 (1991), Abstract; Full Text
Molecular cloning and expression of the rat beta 3-adrenergic receptor: J. G. Granneman, et al.; Mol. Pharmacol. 40, 895 (1991), Abstract;
A preadipocyte clonal line from mouse brown adipose tissue Short- and long-term responses to insulin and beta-adrenergics: C. Forest, et al.; Exp. Cell Res. 168, 218 (1987), Abstract;

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,